Medicare Enrolled
Dr. Jose Silva, MD
Medical Oncology · Chambersburg, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Silva from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Silva?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Silva
Dr. Jose Silva is a medical oncology specialist in Chambersburg, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Silva performed 48,758 Medicare services across 1,373 unique beneficiaries.
Between the years covered by Open Payments, Dr. Silva received a total of $14,115 from 36 pharmaceutical and/or device companies across 141 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Silva is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 3% volume in PA
$14,115 industry payments
Medicare Practice Summary
Medicare Utilization ↗48,758
Medicare services
Top 3% in PA for medical oncology
1,373
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,438 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
13,500 | $1 | $4 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
7,500 | $0 | $6 |
| Pembrolizumab injection (Keytruda) | 6,200 | $43 | $97 |
| Paclitaxel chemotherapy injection | 5,520 | $0 | $2 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
4,880 | $6 | $20 |
| Denosumab injection (Prolia/Xgeva) | 2,280 | $19 | $34 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
1,921 | $21 | $124 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,836 | $0 | $2 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,050 | $1 | $34 |
| Anti-nausea injection (ondansetron/Zofran) | 520 | $0 | $30 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
379 | $2 | $14 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
314 | $12 | $111 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
307 | $96 | $240 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
300 | $2 | $8 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
276 | $112 | $595 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
265 | $11 | $52 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
242 | $99 | $455 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
182 | $22 | $207 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
135 | $48 | $174 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
116 | $1 | $2 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
106 | $21 | $124 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
96 | $7 | $65 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
95 | $66 | $160 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
90 | $137 | $365 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
82 | $55 | $138 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
79 | $49 | $264 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
74 | $1 | $4 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
58 | $20 | $61 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
38 | $16 | $207 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
38 | $40 | $255 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
38 | $1 | $8 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
37 | $10 | $207 |
| New patient office visit, complex (60-74 min) | 37 | $172 | $455 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
32 | $19 | $67 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
32 | $1 | $2 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
30 | $128 | $297 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
23 | $1 | $12 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
18 | $123 | $365 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
18 | $102 | $372 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
14 | $136 | $461 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
29.1% high complexity
69.4% medium
1.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,115
Total received (2018-2024)
Avg $2,016/year across 7 years
Top 28% in PA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
36
Companies
141
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$11,178 (79.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,714 (19.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$223 (1.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$91
2023
$180
2022
$3,530
2021
$830
2020
$261
2019
$7,392
2018
$1,831
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$91
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Incyte Corporation
$5,965
Janssen Biotech, Inc.
$1,855
GlaxoSmithKline, LLC.
$1,625
R-Pharm US LLC
$1,320
AstraZeneca Pharmaceuticals LP
$578
Astellas Pharma US Inc
$535
E.R. Squibb & Sons, L.L.C.
$481
Pharmacyclics LLC, An AbbVie Company
$238
Novartis Pharmaceuticals Corporation
$177
Takeda Pharmaceuticals U.S.A., Inc.
$139
Merck Sharp & Dohme Corporation
$132
Sirtex Medical Inc
$128
Helsinn Therapeutics (U.S.), Inc.
$117
Exelixis Inc.
$97
Bayer HealthCare Pharmaceuticals Inc.
$78
Celgene Corporation
$70
Lilly USA, LLC
$65
PFIZER INC.
$64
GENZYME CORPORATION
$60
Eisai Inc.
$59
Boehringer Ingelheim Pharmaceuticals, Inc.
$49
Genentech USA, Inc.
$40
TerSera Therapeutics LLC
$37
Amgen Inc.
$26
CTI BioPharma Corp.
$24
Rigel Pharmaceuticals, Inc.
$23
Seagen Inc.
$20
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$15
Gilead Sciences, Inc.
$14
Seattle Genetics, Inc.
$12
Tactile Systems Technology Inc
$12
AbbVie, Inc.
$12
Acrotech Biopharma LLC
$12
Cumberland Pharmaceuticals, Inc.
$12
Taiho Oncology, Inc.
$11
Kyowa Kirin, Inc.
$11
Top 3 companies account for 66.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALOXI · Aliqopa · BELEODAQ · BLENREP · BOSULIF · CYRAMZA · Cabometyx · DARZALEX · Ethyol · FARESTON · FLEXITOUCH · GILOTRIF · Halaven · IMBRUVICA · IMFINZI · Imbruvica · Ixempra · JADENU · JAKAFI · KEYTRUDA · KISQALI · LIBTAYO · LYNPARZA · Lenvima · LifeVest · Lonsurf · MEKINIST · NINLARO · Neulasta · OPDIVO · Revlimid · Rezlidhia · SANDOSTATIN LAR · SARCLISA · SIR-Spheres Microspheres · SPRYCEL · TAGRISSO · TASIGNA · TECENTRIQ · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vonjo · XOSPATA · XTANDI · Xofigo · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (79%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Medical oncologists within 10 mi
1
Per 100K population
0.6
County median income
$74,946
Nearest hospital
WELLSPAN CHAMBERSBURG HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Silva is a mixed practice specialist, with above-average Medicare volume (top 3% in PA), with consulting-driven industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Silva experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Silva performed 13,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Silva receive payments from pharmaceutical companies?
Yes. Dr. Silva received a total of $14,115 from 36 companies across 141 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Silva's costs compare to other medical oncologists in Chambersburg?
Dr. Silva's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Silva) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Chambersburg
Browse medical oncologists in Chambersburg ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in PA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in PA
Which PA medical oncologists receive the most from drug and device companies.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology